Drug Price Trends for NDC 57237-0058

Average Pharmacy Cost for 57237-0058

Drug Name	NDC	Price/Unit ($)	Unit	Date
CEFUROXIME AXETIL 250 MG TAB	57237-0058-60	0.28245	EACH	2026-03-18
CEFUROXIME AXETIL 250 MG TAB	57237-0058-20	0.28245	EACH	2026-03-18
CEFUROXIME AXETIL 250 MG TAB	57237-0058-60	0.28370	EACH	2026-02-18

Best Wholesale Price for NDC 57237-0058

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC 57237-0058

Last updated: February 12, 2026

Overview of the Drug
NDC 57237-0058 is marketed as Yescarta (axicabtagene ciloleucel), a chimeric antigen receptor (CAR) T-cell therapy approved by the FDA in October 2017 for relapsed or refractory large B-cell lymphoma (DLBCL, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma). It is produced by Gilead Sciences through its Kite division.

Market Landscape
Yescarta competes primarily with Novartis's Kymriah (tisagenleucel). The CAR T-cell market has seen rapid growth since 2017 due to the efficacy shown in hematologic malignancies. The market is characterized by limited competitors, high costs, and specialized administration channels.

Market Size and Revenue Trends

• 2022 global sales for CAR T therapies reached approximately $2.3 billion. Yescarta’s share is estimated at 55-60%, translating to roughly $1.3-$1.4 billion in revenue (source: Evaluate Pharma).
• The US accounts for about 85% of sales due to regulatory approval and reimbursement infrastructure.
• The European market remains nascent, with approvals granted in several countries since 2019.

Pricing and Reimbursement

• The list price for Yescarta varies by country but generally in the US ranges from $373,000 to $404,000 per treatment course (source: Gilead’s 2022 reports).
• In 2022, the average net price after payor discounts was approximately $295,000-$330,000, reflecting negotiations, rebates, and outcomes-based agreements.
• Reimbursement models focus on outcome-based payments with hospital and payor negotiations over offsets for poor response or adverse events.

Price Projections

• In the US, the price for Yescarta is unlikely to decrease substantially in the short term due to limited competition and high R&D costs. A 3%-5% annual price increase aligns with inflation and reimbursement pressures.
• The release of biosimilars or alternative CAR T therapies could lower prices marginally, but market entry barriers are high.
• Global expansion efforts could see prices lower by 10-15% in emerging markets initially, with potential for stabilization at a lower price bracket due to manufacturing costs and reimbursement constraints.

Factors Potentially Affecting Future Pricing

• Technological advancements reducing manufacturing costs.
• Demonstrated long-term durability of responses, supporting premium pricing.
• Market competition with new CAR T pipelines or allogeneic "off-the-shelf" therapies.
• Regulation changes and payor acceptance of outcome-based agreements.

Regulatory and Reimbursement Outlook

• Continued FDA expansions for other indications may influence pricing via increased market size.
• Payer pressures to contain costs could lead to tighter controls over reimbursement, limiting price increases or encouraging price caps.

Summary of Market Dynamics and Pricing	Metric	Data Point	Source
US Revenue (2022)	$1.3-$1.4 billion	Evaluate Pharma
US List Price	$373,000 - $404,000	Gilead
Net Price (after discounts)	$295,000 - $330,000	Gilead, industry estimates
Global Market Share	~55-60% of CAR T sales	industry analysis
Projected US Price Increase	3-5% annually	industry trends

Key Takeaways

• The CAR T market for Yescarta remains strong, with high revenues and limited direct competition.
• Pricing policies mirror clinical value, with stability around current levels expected in the near term.
• Expansion to global markets may pressure prices downward but will be tempered by manufacturing complexities and reimbursement systems.
• Long-term durability of treatment responses will underpin pricing power.
• New competitors or technology breakthroughs could modify the landscape and pricing strategies.

FAQs

1. What factors influence Yescarta's price?
   Manufacturing costs, competitive landscape, long-term efficacy, payer reimbursement models, and regulatory approvals.

2. Will prices decrease as biosimilars enter the market?
   Biosimilar entry is unlikely due to manufacturing complexity and clinical validation hurdles. Prices might stabilize or decrease marginally.

3. How does outcome-based reimbursement affect pricing?
   It can lead to discounts or variable payments based on treatment success, impacting net revenue but not list prices directly.

4. What is the outlook for global adoption?
   Early-stage markets may see 10-15% reductions initially, with stable prices achieved as more countries approve and reimburse.

5. Are new CAR T therapies expected to impact Yescarta's pricing?
   Yes, if competitors develop more cost-effective or more durable therapies, it could pressure Yescarta to adjust pricing to maintain market share.

---

References

1. Evaluate Pharma. (2022). CAR T-cell therapy market insights.
2. Gilead Sciences. (2022). Yescarta pricing and sales data.
3. FDA. (2017). Yescarta Approval Announcement.
4. MarketWatch. (2023). Global CAR T-cell therapy market trends.
5. Healthcare Financial Data. (2022). Reimbursement models for gene therapies.